The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved LumiraDx’s SARS-CoV-2 RNA STAR Complete.

Developed with non-isothermal nucleic acid amplification qSTAR technology, the new rapid Covid-19 molecular assay is designed to detect nucleic acid from SARS-CoV-2 in upper respiratory swabs collected from Covid-19 suspects by a healthcare provider (HCP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It uses a one step direct method for extracting and amplifying nucleic acid on validated open RT-PCR instruments.

Validated by Coronavirus Test Device Approvals (CTDA), LumiraDx SARS-CoV-2 RNA STAR Complete provides results within 20 minutes and contributes to the efficiency and productivity of labs.

The new assay is also authorised for use by non-symptomatic individuals, as well as others without reason to suspect Covid-19, when either self-collected under a HCP’s supervision or by a HCP.

See Also:

The test showed a positive agreement of 95.4% compared to another high sensitivity RT-PCR assay in clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LumiraDx chief commercial officer David Walton said: “Since the start of the pandemic, we have been pleased to support the UK healthcare system with our LumiraDx SARS-CoV-2 Antigen test, providing high sensitivity Covid-19 antigen testing in emergency departments, healthcare clinics, pharmacies and nursing homes.

“With CDTA and MHRA approvals of LumiraDx SARS-CoV-2 RNA STAR Complete, we look forward to partnering with our service partners to provide high throughput, high sensitivity and high-efficiency Covid-19 molecular testing.

“With the capability to process samples up to ten times faster than traditional RT-PCR methods, we are seeing broad customer demand for testing at multiple settings including airports, events and other public venues.”

The company’s SARS-CoV-2 Antigen Test also received UK CTDA and MHRA approval earlier this month.

Last month, LumiraDx announced that its Covid-19 antigen test is capable of detecting the Omicron variant.